Selected research
Industry Growth & Trends
Global Endometriosis Drugs Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Endometriosis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Endometriosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Endometriosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Endometriosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Endometriosis Drugs market include Takeda Pharmaceutical Company, Pfizer, AbbVie, AstraZeneca, ValiRx, Roivant Sciences, Repros Therapeutics, ObsEva and Neurocrine Biosciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Endometriosis Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Endometriosis Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Endometriosis Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Endometriosis Drugs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Endometriosis Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Endometriosis Drugs Market by Company
Takeda Pharmaceutical Company
Pfizer
AbbVie
AstraZeneca
ValiRx
Roivant Sciences
Repros Therapeutics
ObsEva
Neurocrine Biosciences
Kissei Pharmaceutical
Evotec
Debiopharm Group
Astellas Pharma
Endometriosis Drugs Segment by Type
Chinese Herbs
Progestogens
Hormonal Therapy
Add-back Medication
Endometriosis Drugs Segment by Application
Research Institutes
Hospitals
Clinics
Endometriosis Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endometriosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Endometriosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endometriosis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Endometriosis Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Chinese Herbs
- Progestogens
- Hormonal Therapy
- Add-back Medication
Applications
- Research Institutes
- Hospitals
- Clinics
Companies covered
- Takeda Pharmaceutical Company
- Pfizer
- AbbVie
- AstraZeneca
- ValiRx
- Roivant Sciences
- Repros Therapeutics
- ObsEva
- Neurocrine Biosciences
- Kissei Pharmaceutical
- Evotec
- Debiopharm Group
- Astellas Pharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Endometriosis Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Endometriosis Drugs Market Size by Region (2021-2032)
- 1.4.1 Global Endometriosis Drugs Market Size by Region (2021-2026)
- 1.4.2 Global Endometriosis Drugs Market Size by Region (2027-2032)
- 1.5 Key Regions Endometriosis Drugs Market Size (2021-2032)
- 1.5.1 North America Endometriosis Drugs Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Endometriosis Drugs Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Endometriosis Drugs Market Size Growth Rate (2021-2032)
- 1.5.4 South America Endometriosis Drugs Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Endometriosis Drugs Market Size Growth Rate (2021-2032)
2 Endometriosis Drugs Market by Type
- 2.1 Type Introduction
- 2.1.1 Chinese Herbs
- 2.1.2 Progestogens
- 2.1.3 Hormonal Therapy
- 2.1.4 Add-back Medication
- 2.2 Global Endometriosis Drugs Market Size by Type
- 2.2.1 Global Endometriosis Drugs Market Size Overview by Type (2021-2032)
- 2.2.2 Global Endometriosis Drugs Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Endometriosis Drugs Market Size Forecasted by Type (2027-2032)
- 2.3 Global Endometriosis Drugs Market Size by Regions
- 2.3.1 North America Endometriosis Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Endometriosis Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Endometriosis Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Endometriosis Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Endometriosis Drugs Market Size Breakdown by Type (2021-2026)
3 Endometriosis Drugs Market by Application
- 3.1 Type Introduction
- 3.1.1 Research Institutes
- 3.1.2 Hospitals
- 3.1.3 Clinics
- 3.2 Global Endometriosis Drugs Market Size by Application
- 3.2.1 Global Endometriosis Drugs Market Size Overview by Application (2021-2032)
- 3.2.2 Global Endometriosis Drugs Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Endometriosis Drugs Market Size Forecasted by Application (2027-2032)
- 3.3 Global Endometriosis Drugs Market Size by Regions
- 3.3.1 North America Endometriosis Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Endometriosis Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Endometriosis Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Endometriosis Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Endometriosis Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Endometriosis Drugs Industry Trends
- 4.2 Endometriosis Drugs Industry Drivers
- 4.3 Endometriosis Drugs Industry Opportunities and Challenges
- 4.4 Endometriosis Drugs Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Endometriosis Drugs Revenue (2021-2026)
- 5.2 Global Endometriosis Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Endometriosis Drugs Key Company Headquarters & Area Served
- 5.4 Global Endometriosis Drugs Company, Product Type & Application
- 5.5 Global Endometriosis Drugs Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Endometriosis Drugs Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Endometriosis Drugs Players Market Share by Revenue in 2025
- 5.6.3 2025 Endometriosis Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Takeda Pharmaceutical Company
- 6.1.1 Takeda Pharmaceutical Company Company Information
- 6.1.2 Takeda Pharmaceutical Company Business Overview
- 6.1.3 Takeda Pharmaceutical Company Endometriosis Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Takeda Pharmaceutical Company Endometriosis Drugs Product Portfolio
- 6.1.5 Takeda Pharmaceutical Company Recent Developments
- 6.2 Pfizer
- 6.2.1 Pfizer Company Information
- 6.2.2 Pfizer Business Overview
- 6.2.3 Pfizer Endometriosis Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Pfizer Endometriosis Drugs Product Portfolio
- 6.2.5 Pfizer Recent Developments
- 6.3 AbbVie
- 6.3.1 AbbVie Company Information
- 6.3.2 AbbVie Business Overview
- 6.3.3 AbbVie Endometriosis Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 AbbVie Endometriosis Drugs Product Portfolio
- 6.3.5 AbbVie Recent Developments
- 6.4 AstraZeneca
- 6.4.1 AstraZeneca Company Information
- 6.4.2 AstraZeneca Business Overview
- 6.4.3 AstraZeneca Endometriosis Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 AstraZeneca Endometriosis Drugs Product Portfolio
- 6.4.5 AstraZeneca Recent Developments
- 6.5 ValiRx
- 6.5.1 ValiRx Company Information
- 6.5.2 ValiRx Business Overview
- 6.5.3 ValiRx Endometriosis Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 ValiRx Endometriosis Drugs Product Portfolio
- 6.5.5 ValiRx Recent Developments
- 6.6 Roivant Sciences
- 6.6.1 Roivant Sciences Company Information
- 6.6.2 Roivant Sciences Business Overview
- 6.6.3 Roivant Sciences Endometriosis Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Roivant Sciences Endometriosis Drugs Product Portfolio
- 6.6.5 Roivant Sciences Recent Developments
- 6.7 Repros Therapeutics
- 6.7.1 Repros Therapeutics Company Information
- 6.7.2 Repros Therapeutics Business Overview
- 6.7.3 Repros Therapeutics Endometriosis Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Repros Therapeutics Endometriosis Drugs Product Portfolio
- 6.7.5 Repros Therapeutics Recent Developments
- 6.8 ObsEva
- 6.8.1 ObsEva Company Information
- 6.8.2 ObsEva Business Overview
- 6.8.3 ObsEva Endometriosis Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 ObsEva Endometriosis Drugs Product Portfolio
- 6.8.5 ObsEva Recent Developments
- 6.9 Neurocrine Biosciences
- 6.9.1 Neurocrine Biosciences Company Information
- 6.9.2 Neurocrine Biosciences Business Overview
- 6.9.3 Neurocrine Biosciences Endometriosis Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Neurocrine Biosciences Endometriosis Drugs Product Portfolio
- 6.9.5 Neurocrine Biosciences Recent Developments
- 6.10 Kissei Pharmaceutical
- 6.10.1 Kissei Pharmaceutical Company Information
- 6.10.2 Kissei Pharmaceutical Business Overview
- 6.10.3 Kissei Pharmaceutical Endometriosis Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Kissei Pharmaceutical Endometriosis Drugs Product Portfolio
- 6.10.5 Kissei Pharmaceutical Recent Developments
- 6.11 Evotec
- 6.11.1 Evotec Company Information
- 6.11.2 Evotec Business Overview
- 6.11.3 Evotec Endometriosis Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Evotec Endometriosis Drugs Product Portfolio
- 6.11.5 Evotec Recent Developments
- 6.12 Debiopharm Group
- 6.12.1 Debiopharm Group Company Information
- 6.12.2 Debiopharm Group Business Overview
- 6.12.3 Debiopharm Group Endometriosis Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Debiopharm Group Endometriosis Drugs Product Portfolio
- 6.12.5 Debiopharm Group Recent Developments
- 6.13 Astellas Pharma
- 6.13.1 Astellas Pharma Company Information
- 6.13.2 Astellas Pharma Business Overview
- 6.13.3 Astellas Pharma Endometriosis Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Astellas Pharma Endometriosis Drugs Product Portfolio
- 6.13.5 Astellas Pharma Recent Developments
7 North America
- 7.1 North America Endometriosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Endometriosis Drugs Market Size by Country (2021-2026)
- 7.3 North America Endometriosis Drugs Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Endometriosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Endometriosis Drugs Market Size by Country (2021-2026)
- 8.3 Europe Endometriosis Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Endometriosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Endometriosis Drugs Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Endometriosis Drugs Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Endometriosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Endometriosis Drugs Market Size by Country (2021-2026)
- 10.3 South America Endometriosis Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Endometriosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Endometriosis Drugs Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Endometriosis Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst